Merck KGaA: phase III data shows MS drug efficacy

(CercleFinance.com) - Germany's Merck has presented new efficacy and benefit-risk assessment data for Mavenclad at the Congress of the European Academy of Neurology in Lisbon.


Results of a phase III study showed benefits in patients with relapsing remitting multiple sclerosis, with improvements observed in both relapse rate and magnetic resonance imaging outcomes when compared with placebo, the group said.

Since 2017, Mavenclad is indicated in the European Union for the treatment of adult patients with highly active relapsing multiple sclerosis.

Copyright (c) 2018 CercleFinance.com. All rights reserved.